EuroBiotech: More Articles of Note

ReViral appointed Seth Hetherington as CMO. (Pixabay)

> ViiV Healthcare teamed up with Radboud university medical center in the Netherlands to identify new early-stage HIV drug targets. Statement 

> Amryt received clearance to enroll babies and infants in its phase 3 epidermolysis bullosa trial. The expansion follows an analysis of pharmacokinetic data on patients aged four years and older enrolled in the study. Release 

> ReViral appointed Seth Hetherington as CMO. Hetherington joins ReViral from Genocea Biosciences. Statement 


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Compugen detailed plans to lay off 35% of its staff and consolidate its R&D activities in Israel. The cuts, which largely affect R&D, are intended to ensure Compugen has the money to reach clinical proof-of-concept readouts. Release 

> Quantum Genomics completed enrollment in a pharmacokinetic study of its modified release firibastat tablets. Statement 

> Modus Therapeutics dosed the first cohort in a phase 1 trial of its sickle cell disease drug. Release 

Suggested Articles

Loretta Itri, M.D. has been helping Immunomedics out with its troubled antibody-drug conjugate. Now, she’s signing on as its chief medical officer.

Light Chain Bioscience, a unit of Swiss biotech Novimmune, has been handed a nice royalty milestone check from partner Takeda.

The fund received money from Chinese organizations inside and outside the biopharma industry, enabling CICC Capital to ease past its financing goal.